Exploring the efficacy of extended endocrine therapy in pure mucinous breast carcinoma
Background: This study aims to compare the efficacy of 5- versus 10-year endocrine therapy in pure mucinous breast carcinoma (PMBC), focusing on late recurrence and related factors for personalized treatment. Methods: Patients with PMBC who underwent surgery from 1996 to 2014 at Asan Medical Center...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Breast |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977625005090 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850098099740999680 |
|---|---|
| author | Young-Won Lee Sae-Byul Lee Il Yong Chung Jisun Kim Hee Jeong Kim Beom Seok Ko Byung Ho Son Jong Won Lee Tae-Kyung Robyn Yoo |
| author_facet | Young-Won Lee Sae-Byul Lee Il Yong Chung Jisun Kim Hee Jeong Kim Beom Seok Ko Byung Ho Son Jong Won Lee Tae-Kyung Robyn Yoo |
| author_sort | Young-Won Lee |
| collection | DOAJ |
| description | Background: This study aims to compare the efficacy of 5- versus 10-year endocrine therapy in pure mucinous breast carcinoma (PMBC), focusing on late recurrence and related factors for personalized treatment. Methods: Patients with PMBC who underwent surgery from 1996 to 2014 at Asan Medical Center were included. Recurrence was categorized as early (<5 years) or late (≥5 years). The primary endpoint was disease-free survival in the 5- and 10- year endocrine groups. Subgroup analysis was performed focused on clinically high-risk patients (tumor ≥2 cm, nodal metastasis, or high histologic grade). Results: A total of 489 patients with PMBC were identified. During a follow-up time of 126 months, 35 (7.2 %) patients had an early recurrence, 25 (5.1 %) patients had a late recurrence, and 394 (87.7 %) patients had no recurrence. High histologic grade was the only factor significantly correlated to late recurrence (hazard ratio 6.92, 95 % confidence interval 1.53–31.3). Among the 5-year disease-free survivors (N = 416), 340 (81.7 %) and 76 (18.3 %) patients underwent 5-year and 10-year endocrine therapy, respectively. Endocrine therapy duration did not impact the 10-year disease-free survival rate (5-year [95.4 %] vs. 10-year [97.3 %] endocrine therapy, log-rank test p = 0.504). Subgroup analysis with clinically high-risk patients revealed no survival difference based on the endocrine therapy duration, too. Conclusion: Extended endocrine therapy did not significantly reduce late recurrence in PMBC, even in high-risk groups, underscoring the importance of personalized strategies for sustained outcomes. |
| format | Article |
| id | doaj-art-1063994c09ee4101b853e71c7dbef686 |
| institution | DOAJ |
| issn | 1532-3080 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Breast |
| spelling | doaj-art-1063994c09ee4101b853e71c7dbef6862025-08-20T02:40:48ZengElsevierBreast1532-30802025-08-018210449210.1016/j.breast.2025.104492Exploring the efficacy of extended endocrine therapy in pure mucinous breast carcinomaYoung-Won Lee0Sae-Byul Lee1Il Yong Chung2Jisun Kim3Hee Jeong Kim4Beom Seok Ko5Byung Ho Son6Jong Won Lee7Tae-Kyung Robyn Yoo8Division of Breast and Endocrine Surgery, Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea; Division of Breast Surgery, Department of Surgery, Ulsan University College of Medicine, Asan Medical Center, Seoul, Republic of KoreaDivision of Breast Surgery, Department of Surgery, Ulsan University College of Medicine, Asan Medical Center, Seoul, Republic of KoreaDivision of Breast Surgery, Department of Surgery, Ulsan University College of Medicine, Asan Medical Center, Seoul, Republic of KoreaDivision of Breast Surgery, Department of Surgery, Ulsan University College of Medicine, Asan Medical Center, Seoul, Republic of KoreaDivision of Breast Surgery, Department of Surgery, Ulsan University College of Medicine, Asan Medical Center, Seoul, Republic of KoreaDivision of Breast Surgery, Department of Surgery, Ulsan University College of Medicine, Asan Medical Center, Seoul, Republic of KoreaDivision of Breast Surgery, Department of Surgery, Ulsan University College of Medicine, Asan Medical Center, Seoul, Republic of KoreaDivision of Breast Surgery, Department of Surgery, Ulsan University College of Medicine, Asan Medical Center, Seoul, Republic of KoreaDivision of Breast Surgery, Department of Surgery, Ulsan University College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Corresponding author. 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.Background: This study aims to compare the efficacy of 5- versus 10-year endocrine therapy in pure mucinous breast carcinoma (PMBC), focusing on late recurrence and related factors for personalized treatment. Methods: Patients with PMBC who underwent surgery from 1996 to 2014 at Asan Medical Center were included. Recurrence was categorized as early (<5 years) or late (≥5 years). The primary endpoint was disease-free survival in the 5- and 10- year endocrine groups. Subgroup analysis was performed focused on clinically high-risk patients (tumor ≥2 cm, nodal metastasis, or high histologic grade). Results: A total of 489 patients with PMBC were identified. During a follow-up time of 126 months, 35 (7.2 %) patients had an early recurrence, 25 (5.1 %) patients had a late recurrence, and 394 (87.7 %) patients had no recurrence. High histologic grade was the only factor significantly correlated to late recurrence (hazard ratio 6.92, 95 % confidence interval 1.53–31.3). Among the 5-year disease-free survivors (N = 416), 340 (81.7 %) and 76 (18.3 %) patients underwent 5-year and 10-year endocrine therapy, respectively. Endocrine therapy duration did not impact the 10-year disease-free survival rate (5-year [95.4 %] vs. 10-year [97.3 %] endocrine therapy, log-rank test p = 0.504). Subgroup analysis with clinically high-risk patients revealed no survival difference based on the endocrine therapy duration, too. Conclusion: Extended endocrine therapy did not significantly reduce late recurrence in PMBC, even in high-risk groups, underscoring the importance of personalized strategies for sustained outcomes.http://www.sciencedirect.com/science/article/pii/S0960977625005090Pure mucinous breast carcinomaExtended endocrine therapyHigh-risk patientsLate recurrenceTailored therapy |
| spellingShingle | Young-Won Lee Sae-Byul Lee Il Yong Chung Jisun Kim Hee Jeong Kim Beom Seok Ko Byung Ho Son Jong Won Lee Tae-Kyung Robyn Yoo Exploring the efficacy of extended endocrine therapy in pure mucinous breast carcinoma Breast Pure mucinous breast carcinoma Extended endocrine therapy High-risk patients Late recurrence Tailored therapy |
| title | Exploring the efficacy of extended endocrine therapy in pure mucinous breast carcinoma |
| title_full | Exploring the efficacy of extended endocrine therapy in pure mucinous breast carcinoma |
| title_fullStr | Exploring the efficacy of extended endocrine therapy in pure mucinous breast carcinoma |
| title_full_unstemmed | Exploring the efficacy of extended endocrine therapy in pure mucinous breast carcinoma |
| title_short | Exploring the efficacy of extended endocrine therapy in pure mucinous breast carcinoma |
| title_sort | exploring the efficacy of extended endocrine therapy in pure mucinous breast carcinoma |
| topic | Pure mucinous breast carcinoma Extended endocrine therapy High-risk patients Late recurrence Tailored therapy |
| url | http://www.sciencedirect.com/science/article/pii/S0960977625005090 |
| work_keys_str_mv | AT youngwonlee exploringtheefficacyofextendedendocrinetherapyinpuremucinousbreastcarcinoma AT saebyullee exploringtheefficacyofextendedendocrinetherapyinpuremucinousbreastcarcinoma AT ilyongchung exploringtheefficacyofextendedendocrinetherapyinpuremucinousbreastcarcinoma AT jisunkim exploringtheefficacyofextendedendocrinetherapyinpuremucinousbreastcarcinoma AT heejeongkim exploringtheefficacyofextendedendocrinetherapyinpuremucinousbreastcarcinoma AT beomseokko exploringtheefficacyofextendedendocrinetherapyinpuremucinousbreastcarcinoma AT byunghoson exploringtheefficacyofextendedendocrinetherapyinpuremucinousbreastcarcinoma AT jongwonlee exploringtheefficacyofextendedendocrinetherapyinpuremucinousbreastcarcinoma AT taekyungrobynyoo exploringtheefficacyofextendedendocrinetherapyinpuremucinousbreastcarcinoma |